Sign In  |  Register  |  About Menlo Park  |  Contact Us

Menlo Park, CA
September 01, 2020 1:28pm
7-Day Forecast | Traffic

  • Search Hotels in Menlo Park

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

ProSomnus, Inc. - Common Stock (NQ: OSA )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Apr 17, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ProSomnus, Inc. - Common Stock

< Previous 1 2 3 Next >
Why Avalo Therapeutics Shares Are Trading Higher By 25%; Here Are 20 Stocks Moving Premarket
Gainers 
Via Benzinga
ProSomnus Reports Record Second Quarter 2023 Top-Line Financial Results
From ProSomnus Sleep Technologies, Inc.
Via GlobeNewswire
EXCLUSIVE: ProSomnus Reports Much Smaller Than Expected Q2 Loss, Revenues Inline With Consensus
Obstructive Sleep Apnea treatment provider ProSomnus Inc (NASDAQ: OSA) reported Q2 revenues of $6.9 million, up 43% Y/Y and a sequential revenue increase of 19%, slightly beating the consensus of $6.4... 
Via Benzinga
Earnings Scheduled For August 3, 2023
Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is likely to report quarterly earnings at $1.10 per share on revenue of $512.74 million. 
Via Benzinga
ProSomnus to Design Head-to-Head Clinical Trial vs. Hypoglossal Nerve Stimulation
Preliminary severe Obstructive Sleep Apnea data from FLOSAT study indicates opportunity for head-to-head trial between precision oral appliance therapy and hypoglossal nerve stimulation 
From ProSomnus Sleep Technologies, Inc.
Via GlobeNewswire
ProSomnus Announces Second Quarter 2023 Investor Call and Business Update
From ProSomnus Sleep Technologies, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
71% of Self-identified Snorers Have Never Consulted a Healthcare Professional
National survey identifies major obstacles to treating snoring and sleep issues 
From ProSomnus Sleep Technologies, Inc.
Via GlobeNewswire
Data Presented at the 2023 SLEEP Annual Meeting Strengthens Evidence for ProSomnus Precision Oral Appliance Therapy for the Treatment of Obstructive Sleep Apnea
From ProSomnus Sleep Technologies, Inc.
Via GlobeNewswire
Data Presented at the 2023 American Academy of Dental Sleep Medicine and the American Thoracic Society Meetings Further Validate ProSomnus Precision Oral Appliance Therapy for the Treatment of Obstructive Sleep Apnea
From ProSomnus Sleep Technologies, Inc.
Via GlobeNewswire
ProSomnus Reports First Quarter 2023 Financial Results
From ProSomnus Sleep Technologies, Inc.
Via GlobeNewswire
ProSomnus Announces Q1 2023 Investor Call and Participation in Upcoming Investor Conferences
From ProSomnus Sleep Technologies, Inc.
Via GlobeNewswire
Study to be Presented at European Respiratory Society and European Sleep Research Society’s Sleep and Breathing 2023 Conference Demonstrates Efficacy of ProSomnus Precision Oral Appliances
Study data indicates that ProSomnus precision oral appliances appear to be more efficacious than traditional oral appliances for the treatment of mild, moderate, and severe Obstructive Sleep Apnea 
From ProSomnus Sleep Technologies, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For April 18, 2023
Via Benzinga
ProSomnus® Announces Publication of Four Accepted Abstracts in the Journal of Dental Sleep Medicine in Advance of Annual Meeting
Study results to be presented in oral and poster presentations at 2023 American Academy of Dental Sleep Medicine Annual Meeting 
From ProSomnus Sleep Technologies, Inc.
Via GlobeNewswire
ProSomnus® Receives Additional U.S. Utility Patent Covering Iterative Titration Technology for Company’s Novel Precision Sleep Apnea Medical Devices
From ProSomnus Sleep Technologies, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For April 3, 2023
Via Benzinga
ProSomnus Reports Fourth Quarter and Fiscal Year 2022 Financial Results
From ProSomnus Sleep Technologies, Inc.
Via GlobeNewswire
Earnings Scheduled For March 30, 2023
Companies Reporting Before The Bell • Creative Realities (NASDAQ:CREX) is estimated to report quarterly loss at $0.12 per share on revenue of $10.80 million. 
Via Benzinga
ProSomnus® Receives Patent Allowance Covering Automated Manufacturing Process for Company’s Novel Precision Sleep Apnea Medical Devices
From ProSomnus Sleep Technologies, Inc.
Via GlobeNewswire
ProSomnus to Host Investor Call and Report Fourth Quarter and Full Year 2022 Financial Results on March 30, 2023
From ProSomnus Sleep Technologies, Inc.
Via GlobeNewswire
ProSomnus® Announces Acceptance of Abstract at European Respiratory Society and European Sleep Research Society’s Sleep and Breathing 2023 Conference
From ProSomnus Sleep Technologies, Inc.
Via GlobeNewswire
ProSomnus to Present at Two Upcoming Investor Conferences in March 2023
From ProSomnus Sleep Technologies, Inc.
Via GlobeNewswire
ProSomnus® Appoints Brian Dow as Chief Financial Officer
From ProSomnus Sleep Technologies, Inc.
Via GlobeNewswire
ProSomnus® Provides Business Update and Preliminary 2022 Revenue Guidance
Company commences execution of strategic growth initiatives following Initial Public Offering 
From ProSomnus Sleep Technologies, Inc.
Via GlobeNewswire
EXCLUSIVE: ProSomnus Expands In Medical Device Industry With Strong 2022 Results, What You Need To Know
ProSomnus Inc (NASDAQ: OSA), a front-runner in the medical device industry for the treatment of Obstructive Sleep Apnea, issued its unaudited results for the quarter and full year ending Dec. 31,... 
Via Benzinga
ProSomnus® Announces Acceptance of Abstract for Oral Presentation at Prestigious American Thoracic Society 2023 International Conference
Data from First Line Obstructive Sleep Apnea Treatment Study (FLOSAT) study will be presented for the first time 
From ProSomnus Sleep Technologies, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
ProSomnus® Announces Completion of Enrollment in Antwerp University Hospital’s First Line Obstructive Sleep Apnea Treatment Study (FLOSAT)
From ProSomnus Sleep Technologies, Inc.
Via GlobeNewswire
EXCLUSIVE: ProSomnus Concludes Enrollment In Head To Head Study Comparing Its Sleep Device With Philips'
ProSomnus Inc (NASDAQ: OSA) has completed enrollment in the FLOSAT study, a head-to-head, crossover study comparing t 
Via Benzinga
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MenloPark.com & California Media Partners, LLC. All rights reserved.